The Systolic Heart Failure drugs in development market research report provides comprehensive information on the therapeutics under development for Systolic Heart Failure, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Systolic Heart Failure. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Systolic Heart Failure and features dormant and discontinued products.
GlobalData tracks 34 drugs in development for Systolic Heart Failure by 31 companies/universities/institutes. The top development phase for Systolic Heart Failure is phase ii with 13 drugs in that stage. The Systolic Heart Failure pipeline has 33 drugs in development by companies and one by universities/ institutes. Some of the companies in the Systolic Heart Failure pipeline products market are: Novo Nordisk, Bristol-Myers Squibb and Novartis.
The key targets in the Systolic Heart Failure pipeline products market include Sodium/Glucose Cotransporter 2, Neprilysin, and Type 1 Angiotensin II Receptor.
The key mechanisms of action in the Systolic Heart Failure pipeline product include Sodium/Glucose Cotransporter 2 Inhibitor with four drugs in Pre-Registration. The Systolic Heart Failure pipeline products include eight routes of administration with the top ROA being Oral and seven key molecule types in the Systolic Heart Failure pipeline products market including Small Molecule, and Gene Therapy.
Systolic Heart Failure overview
Systolic heart failure is a cardiovascular disorder marked by specific features, including the enlargement of the heart’s ventricles, resulting in reduced ejection fraction, a measure of the heart’s pumping efficiency. This condition can manifest as either a chronic, long-term issue or an acute, sudden onset event. However, in both forms, a critical factor contributing to the progression of systolic heart failure is left ventricular remodeling. This process involves structural and functional changes in the left ventricle of the heart, ultimately impacting its ability to pump blood effectively. These alterations in heart shape and function lead to a vicious cycle of deteriorating cardiac performance, making left ventricular remodeling a central concern in the management and understanding of systolic heart failure.
For a complete picture of Systolic Heart Failure’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
